You are here

Our science / Clinical Trials / Find a Trial / NCT01147874

Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice

Back to Search Print Save as PDF Bookmark Trial

NCT01147874

Last updated on April 6, 2020
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Modern Research Assoc. PLLC
Dallas, Texas, 75205 United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Psoriasis, Psoriatic Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subject is >18 years of age at the time of consent.

- Subject has a confirmed diagnosis of plaque psoriasis by clinical judgment.

- Subject is able to read and complete questionnaires.

- Subjects planning to undergo radiographic evaluation, should not have any
contraindications to MRI.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- None.

NCT01147874
Pfizer
Completed
Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

Based on your search, you may also be interested in

Psoriatic Arthritis
A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis
NCT03963401
All Genders
18+
Years
Multiple Sites
Psoriasis
Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis
NCT03850483
All Genders
18+
Years
Multiple Sites
Psoriatic Arthritis
Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis
NCT03486457
All Genders
18+
Years
Multiple Sites
Psoriasis
A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis
NCT03895372
All Genders
18+
Years
Multiple Sites
Descriptive Information
Brief Title  ICMJE Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice
Official Title  ICMJE Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice
Brief Summary This is a phase 4, multicenter, randomized, non-therapeutic interventional trial in subjects with psoriasis looking for the prevalence of psoriatic arthritis. Subjects will be seen and evaluated by a dermatologist at visit 1 and by a rheumatologist at visit 2. A subset of subjects will then go on to visit 3 for imaging procedures (x-ray, MRI, and ultrasound).
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Condition  ICMJE
  • Psoriasis
  • Psoriatic Arthritis
Intervention  ICMJE Procedure: lab draws and imaging
1 set of lab draws, imaging consists of radiographic imaging or X-ray, ultrasound and MRI
Study Arms  ICMJE No Intervention: psoriatic arthritis (PsA) questionnaire
Intervention: Procedure: lab draws and imaging
Publications * Mease PJ, Gladman DD, Papp KA, Khraishi MM, Thaçi D, Behrens F, Northington R, Fuiman J, Bananis E, Boggs R, Alvarez D. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2013 Nov;69(5):729-735. doi: 10.1016/j.jaad.2013.07.023. Epub 2013 Aug 24.


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 18, 2012) 		1013
Original Estimated Enrollment  ICMJE
 (submitted: June 17, 2010) 		1000
Actual Study Completion Date  ICMJE July 2011
Actual Primary Completion Date July 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Subject is >18 years of age at the time of consent.
  • Subject has a confirmed diagnosis of plaque psoriasis by clinical judgment.
  • Subject is able to read and complete questionnaires.
  • Subjects planning to undergo radiographic evaluation, should not have any contraindications to MRI.

Exclusion Criteria:

  • None.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Belgium,   Canada,   Denmark,   France,   Germany,   Hungary,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01147874
Other Study ID Numbers  ICMJE 0881A6-4728
B1801032
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Pfizer CT.gov Call Center Pfizer
PRS Account Pfizer
Verification Date April 2012

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now